Obstructive sleep apnea and endothelial progenitor cells

Qing Wang,1,* Qi Wu,2,* Jing Feng,3,4 Xin Sun5 1The Second Respiratory Department of the First People's Hospital of Kunming, Yunnan, People's Republic of China; 2Tianjin Haihe Hospital, Tianjin, People's Republic of China; 3Respiratory Department of Tianjin Medical University...

Full description

Bibliographic Details
Main Authors: Wang Q, Wu Q, Feng J, Sun X
Format: Article
Language:English
Published: Dove Medical Press 2013-10-01
Series:Patient Preference and Adherence
Online Access:http://www.dovepress.com/obstructive-sleep-apnea-and-endothelial-progenitor-cells-a14734
id doaj-bba1e79e718546cb8b772d10aa62af52
record_format Article
spelling doaj-bba1e79e718546cb8b772d10aa62af522020-11-25T00:14:21ZengDove Medical PressPatient Preference and Adherence1177-889X2013-10-012013default10771090Obstructive sleep apnea and endothelial progenitor cellsWang QWu QFeng JSun XQing Wang,1,* Qi Wu,2,* Jing Feng,3,4 Xin Sun5 1The Second Respiratory Department of the First People's Hospital of Kunming, Yunnan, People's Republic of China; 2Tianjin Haihe Hospital, Tianjin, People's Republic of China; 3Respiratory Department of Tianjin Medical University General Hospital, Tianjin, People's Republic of China; 4Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC, USA; 5Respiratory Department of Tianjin Haihe Hospital, Tianjin, People's Republic of China *These authors contributed equally to this work Background: Obstructive sleep apnea (OSA) occurs in 4% of middle-aged men and 2% of middle-aged women in the general population, and the prevalence is even higher in specific patient groups. OSA is an independent risk factor for a variety of cardiovascular diseases. Endothelial injury could be the pivotal determinant in the development of cardiovascular pathology in OSA. Endothelial damage ultimately represents a dynamic balance between the magnitude of injury and the capacity for repair. Bone marrow–derived endothelial progenitor cells (EPCs) within adult peripheral blood present a possible means of vascular maintenance that could home to sites of injury and restore endothelial integrity and normal function. Methods: We summarized pathogenetic mechanisms of OSA and searched for available studies on numbers and functions of EPCs in patients with OSA to explore the potential links between the numbers and functions of EPCs and OSA. In particular, we tried to elucidate the molecular mechanisms of the effects of OSA on EPCs. Conclusion: Intermittent hypoxia cycles and sleep fragmentation are major pathophysiologic characters of OSA. Intermittent hypoxia acts as a trigger of oxidative stress, systemic inflammation, and sympathetic activation. Sleep fragmentation is associated with a burst of sympathetic activation and systemic inflammation. In most studies, a reduction in circulating EPCs has emerged. The possible mechanisms underlying the decrease in the number or function of EPCs include prolonged inflammation response, oxidative stress, increased sympathetic activation, physiological adaptive responses of tissue to hypoxia, reduced EPC mobilization, EPC apoptosis, and functional impairment in untreated OSA. Continuous positive airway pressure (CPAP) therapy for OSA affects the mobilization, apoptosis, and function of EPCs through preventing intermittent hypoxia episodes, improving sleep quality, and reducing systemic inflammation, oxidative stress levels, and sympathetic overactivation. To improve CPAP adherence, the medical staff should pay attention to making the titration trial a comfortable first CPAP experience for the patients; for example, using the most appropriate ventilators or proper humidification. It is also important to give the patients education and support about CPAP use in the follow-up, especially in the early stage of the treatment. Keywords: intermittent hypoxia, systemic inflammation, oxidative stress, sympathetic activation, continuous positive airway pressure adherencehttp://www.dovepress.com/obstructive-sleep-apnea-and-endothelial-progenitor-cells-a14734
collection DOAJ
language English
format Article
sources DOAJ
author Wang Q
Wu Q
Feng J
Sun X
spellingShingle Wang Q
Wu Q
Feng J
Sun X
Obstructive sleep apnea and endothelial progenitor cells
Patient Preference and Adherence
author_facet Wang Q
Wu Q
Feng J
Sun X
author_sort Wang Q
title Obstructive sleep apnea and endothelial progenitor cells
title_short Obstructive sleep apnea and endothelial progenitor cells
title_full Obstructive sleep apnea and endothelial progenitor cells
title_fullStr Obstructive sleep apnea and endothelial progenitor cells
title_full_unstemmed Obstructive sleep apnea and endothelial progenitor cells
title_sort obstructive sleep apnea and endothelial progenitor cells
publisher Dove Medical Press
series Patient Preference and Adherence
issn 1177-889X
publishDate 2013-10-01
description Qing Wang,1,* Qi Wu,2,* Jing Feng,3,4 Xin Sun5 1The Second Respiratory Department of the First People's Hospital of Kunming, Yunnan, People's Republic of China; 2Tianjin Haihe Hospital, Tianjin, People's Republic of China; 3Respiratory Department of Tianjin Medical University General Hospital, Tianjin, People's Republic of China; 4Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC, USA; 5Respiratory Department of Tianjin Haihe Hospital, Tianjin, People's Republic of China *These authors contributed equally to this work Background: Obstructive sleep apnea (OSA) occurs in 4% of middle-aged men and 2% of middle-aged women in the general population, and the prevalence is even higher in specific patient groups. OSA is an independent risk factor for a variety of cardiovascular diseases. Endothelial injury could be the pivotal determinant in the development of cardiovascular pathology in OSA. Endothelial damage ultimately represents a dynamic balance between the magnitude of injury and the capacity for repair. Bone marrow–derived endothelial progenitor cells (EPCs) within adult peripheral blood present a possible means of vascular maintenance that could home to sites of injury and restore endothelial integrity and normal function. Methods: We summarized pathogenetic mechanisms of OSA and searched for available studies on numbers and functions of EPCs in patients with OSA to explore the potential links between the numbers and functions of EPCs and OSA. In particular, we tried to elucidate the molecular mechanisms of the effects of OSA on EPCs. Conclusion: Intermittent hypoxia cycles and sleep fragmentation are major pathophysiologic characters of OSA. Intermittent hypoxia acts as a trigger of oxidative stress, systemic inflammation, and sympathetic activation. Sleep fragmentation is associated with a burst of sympathetic activation and systemic inflammation. In most studies, a reduction in circulating EPCs has emerged. The possible mechanisms underlying the decrease in the number or function of EPCs include prolonged inflammation response, oxidative stress, increased sympathetic activation, physiological adaptive responses of tissue to hypoxia, reduced EPC mobilization, EPC apoptosis, and functional impairment in untreated OSA. Continuous positive airway pressure (CPAP) therapy for OSA affects the mobilization, apoptosis, and function of EPCs through preventing intermittent hypoxia episodes, improving sleep quality, and reducing systemic inflammation, oxidative stress levels, and sympathetic overactivation. To improve CPAP adherence, the medical staff should pay attention to making the titration trial a comfortable first CPAP experience for the patients; for example, using the most appropriate ventilators or proper humidification. It is also important to give the patients education and support about CPAP use in the follow-up, especially in the early stage of the treatment. Keywords: intermittent hypoxia, systemic inflammation, oxidative stress, sympathetic activation, continuous positive airway pressure adherence
url http://www.dovepress.com/obstructive-sleep-apnea-and-endothelial-progenitor-cells-a14734
work_keys_str_mv AT wangq obstructivesleepapneaandendothelialprogenitorcells
AT wuq obstructivesleepapneaandendothelialprogenitorcells
AT fengj obstructivesleepapneaandendothelialprogenitorcells
AT sunx obstructivesleepapneaandendothelialprogenitorcells
_version_ 1725390975046516736